M
17.23
0.64 (3.86%)
| Previous Close | 16.59 |
| Open | 16.91 |
| Volume | 2,901,115 |
| Avg. Volume (3M) | 1,188,904 |
| Market Cap | 1,466,388,224 |
| Price / Book | 5.81 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Diluted EPS (TTM) | -2.30 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 21.11 |
| Operating Cash Flow (TTM) | -139.78 M |
| Levered Free Cash Flow (TTM) | -102.40 M |
| Return on Assets (TTM) | -19.85% |
| Return on Equity (TTM) | -30.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | MoonLake Immunotherapeutics | Mixed | Bearish |
AIStockmoo Score
-1.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -2.5 |
| Average | -1.83 |
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 15.34% |
| % Held by Institutions | 96.70% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |